(Q36299969)

13 August 2017

1 reference

title

Celecoxib and cardiovascular risks (English)

1 reference

13 August 2017

James M Brophy

1

0 references

language of work or name

English

0 references

publication date

1 November 2005

1 reference

Expert Opinion on Drug Safety

13 August 2017

published in

1 reference

13 August 2017

volume

4

1 reference

13 August 2017

issue

6

1 reference

13 August 2017

page(s)

1005-1015

1 reference

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Arthritis medicines and cardiovascular events--"house of coxibs".

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Failing the public health--rofecoxib, Merck, and the FDA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

A coxib a day won't keep the doctor away

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

The need for randomization in the study of intended effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Risk of cardiovascular events associated with selective COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

COX-2 inhibitors--a lesson in unexpected problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

COX-2 inhibitors--lessons in drug safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.6.1005

10.1517/14740338.4.6.1005

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference